Holen Sie sich die Stockscreener-App
5.96
3.25%
-0.20
Handel nachbörslich:
5.90
-0.06
-1.01%
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - Nasdaq
JSPR stock touches 52-week low at $5.22 amid market challenges - Investing.com Nigeria
Objective long/short (JSPR) Report - Stock Traders Daily
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Jasper Therapeutics Announces Presentations of Briquilimab Data at AAAAI 2025 Annual Meeting - Nasdaq
JSPR’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - The InvestChronicle
Selling Buzz: Jasper Therapeutics Inc [JSPR] Chief Operating Officer Mahal Jeetinder Singh sells 900 shares of the company – Knox Daily - Knox Daily
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewswire
Knightscope Achieves Full FedRAMP® Authorization, Unlocking Federal Growth - The Globe and Mail
Inside Jasper's Revolutionary Mast Cell Therapy: Key Updates Coming at Major Healthcare Conference - StockTitan
Jasper Therapeutics Inc (NASDAQ:JSPR) Drops -9.55%, But A Strong Recovery May Be Imminent - Marketing Sentinel
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
How to Take Advantage of moves in (JSPR) - Stock Traders Daily
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $67.75 - Defense World
Insider Selling in Tech Stocks Spikes in Q4 - The Globe and Mail
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Cantor Fitzgerald Forecasts JSPR FY2025 Earnings - Defense World
Research Analysts Set Expectations for JSPR FY2025 Earnings - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Barclays PLC - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Rises By 12.1% - Defense World
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1% - MarketBeat
HC Wainwright Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00 - Defense World
What is HC Wainwright’s Forecast for JSPR Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for JSPR Q1 Earnings? - MarketBeat
Jane Street Group LLC Takes $251,000 Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
What is HC Wainwright’s Estimate for JSPR FY2029 Earnings? - Defense World
Royal Bank of Canada Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $48.00 - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Stock summary: Jasper Therapeutics witnessed loss overall loss of 67.19% throughout the week - Business Upturn
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $40.00 by Analysts at HC Wainwright - MarketBeat
What is HC Wainwright's Forecast for JSPR FY2029 Earnings? - MarketBeat
JSPR stock touches 52-week low at $6.76 amid market shifts - Investing.com
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada - MarketBeat
BMO maintains Jasper Therapeutics Outperform rating By Investing.com - Investing.com Australia
Why Jasper Therapeutics stock plunged 60% in one trading session - Dataconomy
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes urticaria stock outlook - Investing.com India
Quantum Computing Stocks Tumble: Market Reacts to NVIDIA CEO Statement – Market - HPBL
Trading (JSPR) With Integrated Risk Controls - Stock Traders Daily
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy By Investing.com - Investing.com Canada
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
BTIG cuts Jasper Therapeutics price target to $64, maintains Buy - Investing.com India
Buy rating upheld for Jasper Therapeutics stock as briquilimab progresses in trials - Investing.com Nigeria
Oppenheimer maintains $80 target on Jasper Therapeutics stock - Investing.com India
BMO maintains Jasper Therapeutics Outperform rating - Investing.com
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):